<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
    xmlns:admin="http://webns.net/mvcb/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
	<channel>
<title>My RSS Feed</title><link>http://www.vascular.idv.tw/index.html</link><description>Hot News&#x21;</description><dc:language>zh-tw</dc:language><dc:creator>purplemind@mac.com</dc:creator><dc:rights>Copyright 2006 Po Jen Ko</dc:rights><dc:date>2011-06-02T23:08:28+08:00</dc:date><admin:generatorAgent rdf:resource="http://www.realmacsoftware.com/" />
<admin:errorReportsTo rdf:resource="mailto:purplemind@mac.com" /><sy:updatePeriod>hourly</sy:updatePeriod>
<sy:updateFrequency>1</sy:updateFrequency>
<sy:updateBase>2000-01-01T12:00+00:00</sy:updateBase>
<lastBuildDate>Mon, 14 Feb 2011 01:48:16 +0800</lastBuildDate><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x5065;&#x4fdd;&#x5065;&#x4fdd;&#x7d66;&#x4ed8;&#x53ca;&#x6cbb;&#x7642;&#x6a19;&#x6e96;&#xff01;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x65b0;&#x805e;</category><dc:date>2011-06-02T23:08:28+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/7a28893b2789ebb57535598bd20d5547-48.html#unique-entry-id-48</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/7a28893b2789ebb57535598bd20d5547-48.html#unique-entry-id-48</guid><content:encoded><![CDATA[<span style="font:15px STHeitiTC-Light; ">以往要自費數十萬台幣的胸主動脈支架終於健保給付了！自今年</span><span style="font:15px Geneva, serif; ">100</span><span style="font:15px STHeitiTC-Light; ">年六月一日起，只要符合下列適應症，即可得到此治療，治療後若有內漏，也可以用健保補救了：<br /><br /></span><span style="font:12px Geneva, serif; "><br /></span><span style="font:14px Geneva, serif; ">1.</span><span style="font:14px STHeitiTC-Light; ">胸主動脈瘤或胸腹主動脈瘤</span><span style="font:14px Geneva, serif; ">(Thoracic Aortic Aneurysm or Thoracoabdominal Aortic Aneurysm)</span><span style="font:14px STHeitiTC-Light; ">。</span><span style="font:14px Geneva, serif; "><br />(1)</span><span style="font:14px STHeitiTC-Light; ">最大直徑大於等於</span><span style="font:14px Geneva, serif; ">6</span><span style="font:14px STHeitiTC-Light; ">公分</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">或</span><span style="font:14px Geneva, serif; "> <br />(2)</span><span style="font:14px STHeitiTC-Light; ">最大直徑大於等於</span><span style="font:14px Geneva, serif; ">5</span><span style="font:14px STHeitiTC-Light; ">公分</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">但快速擴大</span><span style="font:14px Geneva, serif; ">(</span><span style="font:14px STHeitiTC-Light; ">六個月內直徑增加</span><span style="font:14px Geneva, serif; ">0.5</span><span style="font:14px STHeitiTC-Light; ">公或以上</span><span style="font:14px Geneva, serif; ">)</span><span style="font:14px STHeitiTC-Light; ">。</span><span style="font:14px Geneva, serif; "> <br />(3)</span><span style="font:14px STHeitiTC-Light; ">患者合併典型症狀</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">有破裂之虞或破裂時。</span><span style="font:14px Geneva, serif; "> <br />(4)</span><span style="font:14px STHeitiTC-Light; ">非典型主動脈瘤</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">包括偽主動脈瘤、主動脈瘤合併感染、主動脈食道廔管或腸道廔管、主動</span><span style="font:14px Geneva, serif; "> </span><span style="font:14px STHeitiTC-Light; ">脈氣管廔管。</span><span style="font:14px Geneva, serif; "> <br />2.</span><span style="font:14px STHeitiTC-Light; ">胸主動脈或胸腹主動脈穿透性潰瘍</span><span style="font:14px Geneva, serif; ">(Penetrating Aortic Ulcer,PAU)</span><span style="font:14px STHeitiTC-Light; ">。</span><span style="font:14px Geneva, serif; "> <br />3.</span><span style="font:14px STHeitiTC-Light; ">胸主動脈剝離症</span><span style="font:14px Geneva, serif; ">(Aortic dissection) (1)</span><span style="font:14px STHeitiTC-Light; ">複雜性乙型胸主動脈剝離</span><span style="font:14px Geneva, serif; ">(Complicated Type B Dissection),</span><span style="font:14px STHeitiTC-Light; ">包括持續性胸痛、臟器或下</span><span style="font:14px Geneva, serif; "> </span><span style="font:14px STHeitiTC-Light; ">肢分枝動脈灌流不良、剝離性主動脈瘤大於等於</span><span style="font:14px Geneva, serif; ">6</span><span style="font:14px STHeitiTC-Light; ">公分。</span><span style="font:14px Geneva, serif; "> (2)</span><span style="font:14px STHeitiTC-Light; ">急性甲型胸主動脈剝離須進行複合式全主動脈弓手術</span><span style="font:14px Geneva, serif; ">(Hybrid Type A Surgery)</span><span style="font:14px STHeitiTC-Light; ">。</span><span style="font:14px Geneva, serif; "> 4.</span><span style="font:14px STHeitiTC-Light; ">先天性胸主動脈狹窄或分枝異常</span><span style="font:14px Geneva, serif; ">(Coarctation or Aberrant Artery from Aorta)(</span><span style="font:14px STHeitiTC-Light; ">有症狀的</span><span style="font:14px Geneva, serif; "> </span><span style="font:14px STHeitiTC-Light; ">分枝異常且無法以栓塞治療時</span><span style="font:14px Geneva, serif; ">)</span><span style="font:14px STHeitiTC-Light; ">。</span><span style="font:14px Geneva, serif; "> <br />5.</span><span style="font:14px STHeitiTC-Light; ">創傷性胸主動脈破裂</span><span style="font:14px Geneva, serif; ">(Traumatic Aortic Rupture)</span><span style="font:14px STHeitiTC-Light; ">。<br /></span><span style="font:14px Geneva, serif; "> </span><span style="font:14px STHeitiTC-Light; ">二、針對裝置胸主動脈支架手術出院後之滲漏特殊個案</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">需另以支架修補時</span><span style="font:14px Geneva, serif; ">,</span><span style="font:14px STHeitiTC-Light; ">可按實際醫療需</span><span style="font:14px Geneva, serif; "> </span><span style="font:14px STHeitiTC-Light; ">要使用。<br /></span>]]></content:encoded></item><item><title>&#x5c0f;&#x50b7;&#x53e3;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#xfe63;&#x80a1;&#x52d5;&#x8108;&#x7e5e;&#x9053;&#x624b;&#x8853;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2011-03-02T23:18:59+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/4653a3d0e3aa402006a6336af526c419-47.html#unique-entry-id-47</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/4653a3d0e3aa402006a6336af526c419-47.html#unique-entry-id-47</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px STHeitiTC-Light; ">JVS (Journal of Vascular Surgery) 2011 vol. 53 (3) pp. 870-5刊出的德國人作的臨床新研究報告。內容是用小傷口來作主動脈到雙側股動脈的繞道手術！傷口真的很小！</span></p>]]></content:encoded></item><item><title>&#x9999;&#x6e2f;&#x4eba;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x60a3;&#x7387;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2011-02-17T23:59:11+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/16b58b7f9435b68b8bcfda3dd225854d-46.html#unique-entry-id-46</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/16b58b7f9435b68b8bcfda3dd225854d-46.html#unique-entry-id-46</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px STHeitiTC-Light; ">香港中文大學放射科余醫師發表研究指出，他們七年來的篩檢發現，香港男性六十歲以上有百分之三點四四患有腹主動 脈瘤，而女性則是百分之零點八六。<br />由此比例推估，全香港的腹主動脈瘤患者超過兩萬六千人人！<br /></span><span style="font:12px STHeitiTC-Light; "><a href="http://news.hkheadline.com/dailynews/content_hk/2011/02/14/139033.asp" rel="external">連結</a></span><span style="font:12px STHeitiTC-Light; "><br />註：香港也是華人社會，看來台灣的患者也不少，不能忽視！</span></p>]]></content:encoded></item><item><title>&#x652f;&#x67b6;&#x5c0d;&#x65bc;&#x7834;&#x88c2;&#x7684;&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x6cbb;&#x7642;&#x8f03;&#x597d;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2011-02-16T00:58:51+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/b30c461b0ce81f9215b1a161123a9cfe-45.html#unique-entry-id-45</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/b30c461b0ce81f9215b1a161123a9cfe-45.html#unique-entry-id-45</guid><content:encoded><![CDATA[<span style="font:12px STHeitiTC-Light; color:#262626;">血管腔內支架治療對於破裂的胸主動脈瘤（降主動脈瘤），有較低的死亡率，中風率及截癱率，是較理想的選擇！</span>]]></content:encoded></item><item><title>&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x6cbb;&#x7642;&#xff1a;&#x652f;&#x67b6;&#x6bd4;&#x50b3;&#x7d71;&#x624b;&#x8853;&#x7684;&#x9577;&#x671f;&#x5b58;&#x6d3b;&#x7387;&#x597d;&#xff01;&#xa;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x6cbb;&#x7642;&#xff1a;&#x652f;&#x67b6;&#x6bd4;&#x50b3;&#x7d71;&#x624b;&#x8853;&#x7684;&#x9577;&#x671f;&#x5b58;&#x6d3b;&#x7387;&#x597d;&#xff01;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x6cbb;&#x7642;&#xff1a;&#x652f;&#x67b6;&#x6bd4;&#x50b3;&#x7d71;&#x624b;&#x8853;&#x7684;&#x9577;&#x671f;&#x5b58;&#x6d3b;&#x7387;&#x597d;&#xff01;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2011-02-14T01:49:40+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/d53f9b737b6d842452f083b54206ce07-44.html#unique-entry-id-44</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/d53f9b737b6d842452f083b54206ce07-44.html#unique-entry-id-44</guid><content:encoded><![CDATA[<span style="font:12px STHeitiTC-Light; ">在美國南方血管外科學會的年會上，Dr. Brenton E. Quoinney發表的研究報告顯示，支架比傳統手術能讓病人的長期存活較好。他研究了自1999-2009的病例，發現主動脈瘤用支架治療的患者五年死亡率是36% 而傳統手術則是48%, 有明顯差異！<br /></span>]]></content:encoded></item><item><title>&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x6cbb;&#x7642;&#x901a;&#x904e;&#x5065;&#x4fdd;&#x7d66;&#x4ed8;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2010-02-08T23:31:12+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/fdcacd44781cdbcdbd4d1a088a0c89d5-43.html#unique-entry-id-43</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/fdcacd44781cdbcdbd4d1a088a0c89d5-43.html#unique-entry-id-43</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">以往低侵襲性的主動脈支架必需要病人自費，約需四五十萬元。但今年二月一日開始，健保局已經同意開始此一治療的健保給付了。自二月始，Cook的支架及Gore的支架都有健保給付了。而另一家Medtronic的支架，今年也通過給付了。</span></p>]]></content:encoded></item><item><title>Medtronic Talent&#x652f;&#x67b6;&#x5f97;&#x5230;&#x8a31;&#x53ef;&#x8b49;&#x4e86;&#x3002;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2009-10-29T01:21:15+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/4e704040d53b84b5cd90e36987394796-42.html#unique-entry-id-42</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/4e704040d53b84b5cd90e36987394796-42.html#unique-entry-id-42</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">終於國內在除了Cook的Zenith, Gore的Excluder及Medtronic的AneuRx之外，現在又核淮了另一種在歐美巿佔率頗大的腹主動脈支架，Medtronic的Talent. <br />Talent的特色為Nitinol骨架，以及具有腎動脈上的裸支架(suprarenal bare stent). <br />所以目前國內的腹主動脈瘤支架共有來自三家公司的四種支架，　Zenith, Excluder, AneuRx, Talent.</span>]]></content:encoded></item><item><title>&#x8d85;&#x97f3;&#x6ce2;&#x7be9;&#x6aa2;&#x6709;&#x52a9;&#x65bc;&#x964d;&#x4f4e;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x6b7b;&#x4ea1;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2009-07-01T23:59:53+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/8b320096497dbd4c2b27724917165737-41.html#unique-entry-id-41</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/8b320096497dbd4c2b27724917165737-41.html#unique-entry-id-41</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">2009年的大英醫學期刊British Medical Journal刊出了一篇</span><span style="font:12px LiHeiPro; "><a href="http://www.bmj.com/cgi/content/full/338/jun24_2/b2307" rel="external">研究報告</a></span><span style="font:12px LiHeiPro; ">，是有關於英國的腹主動脈瘤篩檢，顯示出篩檢的確可以降低這群人長期因主動脈破裂的死亡率。<br />對這一群人進行廣泛性的超音波篩檢是值得的!<br />並且，如果要提高檢檢的效果，就是要提高參力篩檢的普及率。</span>]]></content:encoded></item><item><title>&#x7814;&#x7a76;&#x986f;&#x793a;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x6b7b;&#x4ea1;&#x7387;&#x8f03;&#x4f4e;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2009-06-26T22:22:54+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/d8c73424e6a6d5853b69dcfd4c207f3b-40.html#unique-entry-id-40</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/d8c73424e6a6d5853b69dcfd4c207f3b-40.html#unique-entry-id-40</guid><content:encoded><![CDATA[<span style="font:14px LiHeiPro; ">今年的美國血管外科年會，有一篇發報告是有關</span><span style="font:14px LiHeiPro; "><a href="http://clinicaltrials.gov/ct2/show/NCT00094575" rel="external">OVER　study</a></span><span style="font:14px LiHeiPro; ">, 是主動脈支架比較開放式手術的死亡率比較。又是一個證明支架手術低死亡率的研究！<br />在這研究中，是前瞻式的隨機分配研究。所有的病人隨機分配成支架治療及開放式手術治療。<br /></span><span style="font:14px LiHeiPro; "><a href="http://www.cardiologytoday.com/view.aspx?rid=40926" rel="external">會中提到</a></span><span style="font:14px LiHeiPro; ">，開放式手術的病人，三十天死亡率是2.3%,而支架手術是0.2%!</span>]]></content:encoded></item><item><title>&#x7528;&#x652f;&#x67b6;&#x4f86;&#x6cbb;&#x7642;&#x4e3b;&#x52d5;&#x8108;&#x5916;&#x50b7;&#x662f;&#x597d;&#x7684;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2009-06-18T22:48:31+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/4d5c26342d1db47c31a4596ed36b36a0-39.html#unique-entry-id-39</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/4d5c26342d1db47c31a4596ed36b36a0-39.html#unique-entry-id-39</guid><content:encoded><![CDATA[<span style="font:13px LiHeiPro; color:#000000;">在</span><span style="font:13px Courier, mono; color:#000000;">journal of thoracic and cardiovascular surgery </span><span style="font:13px LiHeiPro; color:#000000;">上的一篇</span><span style="font:13px LiHeiPro; color:#000000;"><a href="http://www.jtcvsonline.org/article/PIIS0022522309004681/abstract?rss=yes" rel="external">論文</a></span><span style="font:13px LiHeiPro; color:#000000;">，出自</span><span style="font:14px Courier, mono; ">Vascular Surgery Division of the Thorax Institute, Hospital Clinic, Barcelona, Spain</span><span style="font:14px LiHeiPro; ">西班牙</span><span style="font:14px Courier, mono; ">.<br /></span><span style="font:14px LiHeiPro; ">在他們十年的經驗，</span><span style="font:14px Courier, mono; ">20</span><span style="font:14px LiHeiPro; ">個高速外傷主動脈損傷的病人，都是多重創傷，全部以支架療。平均手術時間只有</span><span style="font:14px Courier, mono; ">74</span><span style="font:14px LiHeiPro; ">分，且只有一個死亡。顯示，這個方法對於多重創傷病人的胸主動脈損傷有好的中期及短期治療成效。</span>]]></content:encoded></item><item><title>&#x652f;&#x67b6;&#x5c0d;&#x65bc;&#x7834;&#x88c2;&#x7684;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x6548;&#x679c;&#x66f4;&#x597d;&#xff01;University of Washinton&#x7684;&#x7d93;&#x9a57;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2009-06-17T23:07:34+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/232facdc179e47d7509b237a4cf41cca-38.html#unique-entry-id-38</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/232facdc179e47d7509b237a4cf41cca-38.html#unique-entry-id-38</guid><content:encoded><![CDATA[<span style="font:13px LiHeiPro; color:#000000;">Seatle的University of Washington在第63屆的SVS年會上，發表了支架</span><span style="font:13px LiHeiPro; color:#000000;"><a href="http://www.newswise.com/articles/view/553010/" rel="external">治療破裂腹主動脈瘤的報告</a></span><span style="font:13px LiHeiPro; color:#000000;">。<br />他們對於腹主動脈瘤設定了一套有制度的標準流程，並且引進用支架來治療破裂的腹主動脈瘤。他們比較了這種治療法施行之前及之後的死亡率，發現有系統地並且有條理地用支架來治療明顯地降低了死亡率！30天死亡率從56%降到37%.　(用此方法，約有一半的病人可以用支架，而支架組的病人死亡19%, 開腹組的病人死亡率58%.）<br />他們的治療破裂腹主動脈瘤的流程包括以下重點：<br />快速地主動脈內氣球阻斷<br />故意地降低血壓<br />儘可能地以支架治療<br /><br /></span>]]></content:encoded></item><item><title>&#x9577;&#x5e9a;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x9580;&#x8a3a;&#x4e0a;&#x8def;&#x4e86;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2009-05-05T23:10:11+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/5fc4f49eb5458f9a4e06d0914577581d-37.html#unique-entry-id-37</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/5fc4f49eb5458f9a4e06d0914577581d-37.html#unique-entry-id-37</guid><content:encoded><![CDATA[<span style="font:13px LiHeiPro; color:#000000;">長庚醫院血管外科為了針對胸主動脈瘤，腹主動脈瘤作更完整，有效率的診斷及治療，特地開設了主動脈瘤門診。看診內容為主動脈瘤及週邊動脈瘤患者的診斷，諮詢，治療建議及術後追蹤。</span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">


</span><span style="font:13px LiHeiPro; color:#000000;"><br />門診時間：</span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">
<br />
</span><span style="font:13px LiHeiPro; color:#000000;">林口醫學中心；週五上午<br /></span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">
</span><span style="font:13px LiHeiPro; color:#000000;">（第一，三週為謝宏昌醫師，第二四週為黃耀廣醫師）<br /></span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">
</span><span style="font:13px LiHeiPro; color:#000000;">台北長庚門診：週二上午<br /></span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">
</span><span style="font:13px LiHeiPro; color:#000000;">（第一，三週為柯博仁醫師，第二四週為李浩睿醫師）<br /></span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">

</span><span style="font:13px LiHeiPro; color:#000000;"><a href="http://www.cgmh.org.tw/cghrms/2004_rms/rms_tpe_m.htm" rel="external">台北長庚掛號</a></span><span style="font:13px LiHeiPro; color:#000000;">（週二）　請點選聯合門診＞主動脈瘤特別門診<br /></span><span style="font:13px &#39;Lucida Grande&#39;, LucidaGrande, Verdana, sans-serif; color:#000000;">
</span><span style="font:13px LiHeiPro; color:#000000;"><a href="http://www.cgmh.org.tw/cghrms/2004_rms/rms_lnk_m.htm" rel="self">林口長庚掛號</a></span><span style="font:13px LiHeiPro; color:#000000;">（週五）</span>]]></content:encoded></item><item><title>&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x5c0d;&#x65bc;&#x7834;&#x88c2;&#x6027;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x66f4;&#x5b89;&#x5168;&#xff01;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2009-04-01T23:57:16+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/fbc40d81ada134a69b9193ffee76eeba-36.html#unique-entry-id-36</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/fbc40d81ada134a69b9193ffee76eeba-36.html#unique-entry-id-36</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">今年的著名專業期刊journal of vascular surgery四月號中的一篇研究報告指出：使用支架治療對於破裂的腹主動脈瘤治療成效更好</span>]]></content:encoded></item><item><title>&#x9b4f;&#x931a;&#x6559;&#x6388;&#x767c;&#x660e;&#x65b0;&#x578b;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#x624b;&#x8853;&#x7528;&#x4eba;&#x5de5;&#x8840;&#x7ba1;&#x63a5;&#x74b0;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2009-02-20T22:52:30+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/b3e46a20f41fe14a93909e44f581fc75-35.html#unique-entry-id-35</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/b3e46a20f41fe14a93909e44f581fc75-35.html#unique-entry-id-35</guid><content:encoded><![CDATA[<span style="font:24px LiGothicMed; color:#3E6795;"><a href="http://news.sina.com.tw/article/20090219/1393482.html" rel="external">主動脈剝離新利器-人工血管接環</a></span><span style="font:24px LiGothicMed; color:#3E6795;"><br /></span><span style="font:16px LiHeiPro; color:#000000;">用這種套環來處理主動脈剝離手術，可以不用縫合。</span>]]></content:encoded></item><item><title>Gore TAG&#x6208;&#x723e;&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x7684;&#x5169;&#x5e74;&#x6210;&#x679c;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2008-10-24T22:48:58+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/1ddb4f1065b385b80948cc6b0dfc751d-34.html#unique-entry-id-34</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/1ddb4f1065b385b80948cc6b0dfc751d-34.html#unique-entry-id-34</guid><content:encoded><![CDATA[Gore TAG<span style="font:12px LiHeiPro; ">戈爾胸主動脈支架在美國得到</span>FDA<span style="font:12px LiHeiPro; ">的認證有兩年多了（自</span>2005),<span style="font:12px LiHeiPro; ">至今</span>,<span style="font:12px LiHeiPro; ">仍是</span>FDA<span style="font:12px LiHeiPro; ">唯一認證的胸主支架。美國杜克大學在最近</span>,<span style="font:12px LiHeiPro; ">於學術雜誌</span>ATS<span style="font:12px LiHeiPro; ">上發表了他們的兩年成果</span>,<span style="font:12px LiHeiPro; ">看看</span>TAG<span style="font:12px LiHeiPro; ">的</span><span style="font:12px LiHeiPro; "><a href="March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A "hybrid" approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone.<br /><br />http://ats.ctsnetjournals.org/cgi/content/abstract/86/5/1530" rel="self">成果</a></span><span style="font:12px LiHeiPro; ">。</span><br /><span style="font:12px LiHeiPro; ">從</span>March 23, 2005,<span style="font:12px LiHeiPro; ">到</span> March 23, 2007, <span style="font:12px LiHeiPro; ">共</span> 91 <span style="font:12px LiHeiPro; ">例的胸主動脈支架</span>. <span style="font:12px LiHeiPro; ">其中有百分之</span>91%<span style="font:12px LiHeiPro; ">用</span> TAG <span style="font:12px LiHeiPro; ">。其中</span> (n = 43; 52%)<span style="font:12px LiHeiPro; ">是真性的胸主動脈瘤</span>,  (n = 30; 36%)<span style="font:12px LiHeiPro; ">是急性或慢性的主動脈剝離（夾層）</span>, <span style="font:12px LiHeiPro; ">外傷性有</span>(n = 7; 8%), <span style="font:12px LiHeiPro; ">主動脈手術後的假性動脈瘤有</span> (n = 3; 4%). <span style="font:12px LiHeiPro; ">其中</span>20%<span style="font:12px LiHeiPro; ">同時加行其它繞道手術。<br />手術技術成功率是</span>98.8% (n = 82/83). <span style="font:12px LiHeiPro; ">死亡率是</span>3.6% (n = 3 each). <span style="font:12px LiHeiPro; ">截癱是</span>2.4% (n = 2). <span style="font:12px LiHeiPro; ">有</span> 7.2% (n = 6)<span style="font:12px LiHeiPro; ">在三十天內需要再介入</span>reintervention. <span style="font:12px LiHeiPro; ">追蹤了</span>14 &plusmn; 8 <span style="font:12px LiHeiPro; ">月</span> (range 0&ndash;28), <span style="font:12px LiHeiPro; ">有一例因動脈瘤體破裂而死亡</span>(1.2%) ,<span style="font:12px LiHeiPro; ">有一例轉行開放性手術</span>(1.2%).<br /><span style="font:12px LiHeiPro; ">這樣樣的成功率和結果</span>,<span style="font:12px LiHeiPro; ">看來不錯。所以</span>,<span style="font:12px LiHeiPro; ">在他們的報告中，有約百分之五十的案例是所謂的</span>off label use. <span style="font:12px LiHeiPro; ">而且有百分之二十是加行了繞道（</span>hybrid procedure).]]></content:encoded></item><item><title>&#x7528;&#x652f;&#x67b6;&#x4f86;&#x6cbb;&#x7642;&#x80f8;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;thoracoabdominal aneurysm&#x7684;&#x7d50;&#x679c;&#x662f;&#x4e0d;&#x932f;&#x7684;&#xfe63;UPMC&#x7684;&#x5831;&#x544a;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2008-10-10T22:24:48+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/b9e0f63298345b58dc9402bb7716a3a1-33.html#unique-entry-id-33</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/b9e0f63298345b58dc9402bb7716a3a1-33.html#unique-entry-id-33</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">用支架來治療胸腹主動脈瘤thoracoabdominal aneurysm的結果是不錯的﹣</span><span style="font:12px LiHeiPro; "><a href="http://ejcts.ctsnetjournals.org/cgi/content/abstract/34/4/810" rel="external">UPMC的報告</a></span><span style="font:12px LiHeiPro; ">指出，用這樣來治療，三十天的死亡率是4.8%,而且一年的存活率是80%</span>]]></content:encoded></item><item><title>&#x5c0d;&#x65bc;&#x6709;&#x75c7;&#x72c0;B&#x578b;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#x525d;&#x96e2;&#x2c;&#x652f;&#x67b6;&#x662f;&#x5b58;&#x6d3b;&#x7387;&#x8f03;&#x9ad8;&#x7684;&#x6cbb;&#x7642;&#x65b9;&#x5f0f;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2008-09-24T00:11:04+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/40fa1b6ca22ad20b142a0c6b662156ed-32.html#unique-entry-id-32</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/40fa1b6ca22ad20b142a0c6b662156ed-32.html#unique-entry-id-32</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">對於有症狀B型的主動脈剝離,支架是存活率較高的治療方式</span>]]></content:encoded></item><item><title>&#x4f5c;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x6642;&#x662f;&#x5426;&#x53ef;&#x4ee5;&#x84cb;&#x6389;celiac trunk&#x7684;&#x8a55;&#x4f30;&#x65b9;&#x6cd5;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2008-08-26T15:37:10+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/e44531f6b964f16cd6bf48b115f23946-31.html#unique-entry-id-31</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/e44531f6b964f16cd6bf48b115f23946-31.html#unique-entry-id-31</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">在九月分的</span><span style="font:12px LiHeiPro; "><a href="http://www.ejves.com/article/PIIS1078588408002244/abstract?rss=yes" rel="external">European Journal of Vascular and Endovascular Surgery</a></span><span style="font:12px LiHeiPro; ">上，德國科隆大學有一篇研究是有關在作主動脈支架時評估Celiac trunk是否能覆蓋的作法。他們是在作手術時，作主動脈造影來評估celiac trunk,然後用血管內氣球將血管塞住，同時再作一次造影，模擬支架蓋住後的血流情形。如果這樣的造影有看到明顯的側枝循環存在，就可以放心地將血管蓋住了。<br />他們用這種方法作了五個case,都獲得成功。<br /><br /></span><span style="font:12px LiHeiPro; "><a href="http://www.ejves.com/article/PIIS1078588408002244/abstract?rss=yes" rel="external"> 連結</a></span>]]></content:encoded></item><item><title>&#x6208;&#x723e;&#x7684;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;Excluder2008&#x5e74;&#x4e03;&#x6708;&#x6b63;&#x5f0f;&#x5728;&#x53f0;&#x4e0a;&#x5dff;&#x4f7f;&#x7528;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2008-07-29T09:12:47+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/a862455d1d32a3be1c7baf460531299a-30.html#unique-entry-id-30</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/a862455d1d32a3be1c7baf460531299a-30.html#unique-entry-id-30</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">腹主動脈支架Excluder2008年七月正式在台上巿使用</span>]]></content:encoded></item><item><title>Medtronic &#x7684;Talent&#x3000;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x901a;&#x904e;FDA</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2008-05-01T19:45:02+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/a78b492500a032bc79aedd9e9d4eadd2-29.html#unique-entry-id-29</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/a78b492500a032bc79aedd9e9d4eadd2-29.html#unique-entry-id-29</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">Medtronic 的Talent　腹主動脈支架通過FDA<br /><br />Medtronic 公司宣布他們的Talent 腹主動脈瘤支架日前通過美國食品藥物局FDA的許可。</span>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x652f;&#x67b6;&#x6cbb;&#x7642;TX2&#x4e00;&#x5e74;&#x671f;&#x7d50;&#x679c;&#x767c;&#x8868;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2008-02-07T15:28:05+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/eb3bee9b2281a2e0445cbb1daca27922-28.html#unique-entry-id-28</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/eb3bee9b2281a2e0445cbb1daca27922-28.html#unique-entry-id-28</guid><content:encoded><![CDATA[2008<span style="font:12px LiHeiPro; ">一月份的專業血管外科期刊</span><span style="font:12px LiHeiPro; "><a href="http://www.jvascsurg.org/article/PIIS074152140701693X/abstract" rel="external">Journal of Vascular Surgery</a></span><span style="font:12px LiHeiPro; ">發表了有關Cook公司的TX2胸主動脈支架的一年（初期）結果</span>]]></content:encoded></item><item><title>&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x652f;&#x67b6;&#x6bd4;&#x958b;&#x8179;&#x624b;&#x8853;&#x5b89;&#x5168;&#xff01;&#xff08;&#x6700;&#x65b0;&#x7814;&#x7a76;&#xff09;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2008-02-07T14:22:55+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/39b3ae5c6771e52e32cfcd2846ba476c-27.html#unique-entry-id-27</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/39b3ae5c6771e52e32cfcd2846ba476c-27.html#unique-entry-id-27</guid><content:encoded><![CDATA[<span style="font:13px LiHeiPro; ">在</span><span style="font:13px Courier, mono; ">2008Jan</span><span style="font:13px LiHeiPro; ">的著名醫學期刊</span><span style="font:13px Courier, mono; "> </span><span style="font:13px LiHeiPro; ">新英格蘭醫學期刊</span><span style="font:13px Courier, mono; ">Newengland Journal of Medicine</span><span style="font:13px LiHeiPro; ">上的一篇相當</span><span style="font:13px LiHeiPro; "><a href="http://content.nejm.org/cgi/content/short/358/5/464" rel="external">大規模的研究</a></span><span style="font:13px LiHeiPro; ">顯示，在</span><span style="font:13px Courier, mono; ">22,830 </span><span style="font:13px LiHeiPro; ">名腹主動脈瘤條件相當的病人當中，他們比較了用支架手術和開腹手術的結果差別。<br />結論是，支架手術對於腹主動脈瘤是比較安全的治療方式。</span>]]></content:encoded></item><item><title>&#x5230;&#x5e95;&#x8981;&#x591a;&#x5c11;&#x7d93;&#x9a57;&#xff0c;&#x624d;&#x80fd;&#x7b97;&#x6709;&#x8cc7;&#x683c;&#x4f5c;&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x624b;&#x8853;&#x5462;&#xff1f;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2007-08-19T23:30:37+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/c8bc02328aff1f4df9ef83be7d128063-26.html#unique-entry-id-26</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/c8bc02328aff1f4df9ef83be7d128063-26.html#unique-entry-id-26</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">對於胸主動脈支架而言，到底要多少例才能累積足夠的能力呢？答案是：5-10例！</span>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x8840;&#x7ba1;&#x652f;&#x67b6;&#x7684;&#x61c9;&#x7528;&#x7bc4;&#x570d;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2007-08-12T15:22:33+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/bf82892e42b5bb1438c360c926a90eb5-25.html#unique-entry-id-25</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/bf82892e42b5bb1438c360c926a90eb5-25.html#unique-entry-id-25</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">有那些胸主動脈的疾病是可能用支架來治療的呢？主動脈瘤，主動脈剝離（夾層），主動脈創傷。</span></p>]]></content:encoded></item><item><title>&#x9ad8;&#x624b;&#x8853;&#x5371;&#x96aa;&#x7fa4;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x75c5;&#x4eba;&#x4e5f;&#x5408;&#x9069;&#x4ee5;&#x8840;&#x7ba1;&#x652f;&#x67b6;&#x4f86;&#x6cbb;&#x7642;&#xff01;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-06-23T23:27:49+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/d89cd8f32ac6cd94fb364b09bda4f353-24.html#unique-entry-id-24</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/d89cd8f32ac6cd94fb364b09bda4f353-24.html#unique-entry-id-24</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">他們從2001-2004的全美腹主動脈瘤支架的資料發現，主動脈支架治療，對於高手術風險的主動脈瘤病人而言，也是很安全的。</span></p>]]></content:encoded></item><item><title>&#x597d;&#x6587;&#x7ae0;&#xff1a;endoleak &#x7684;detection&#x21; (Radiology)</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2007-05-25T12:55:27+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/a869643b533dab03553157ce2779c503-23.html#unique-entry-id-23</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/a869643b533dab03553157ce2779c503-23.html#unique-entry-id-23</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">這一篇在Radiology上刊出的review article</span></p>]]></content:encoded></item><item><title>&#x7121;&#x7dda;&#x611f;&#x61c9;&#x5668;&#x76e3;&#x63a7;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7834;&#x88c2;&#x9810;&#x6e2c;&#x7cfb;&#x7d71;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-05-22T20:21:44+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/87b5b4c54532f10148261a3f608de49a-22.html#unique-entry-id-22</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/87b5b4c54532f10148261a3f608de49a-22.html#unique-entry-id-22</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">日本慈惠醫科大學，血管外科的大木隆生醫師，研發了一套無線感知的感應器</span></p>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7db2;&#x7ad9;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2007-05-21T00:04:45+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/921578e18261a3b830fb7bdca67be333-21.html#unique-entry-id-21</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/921578e18261a3b830fb7bdca67be333-21.html#unique-entry-id-21</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">內有有關</span><span style="font:12px LiHeiPro; "><a href="http://web.mac.com/purplemind/iWeb/TEVAR/" rel="external">胸部主動脈瘤</a></span><span style="font:12px LiHeiPro; ">的知識</span></p>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x8840;&#x7ba1;&#x652f;&#x67b6;TEVAR:&#x7121;&#x75c7;&#x72c0;&#x4e14;&#x9ad8;&#x624b;&#x8853;&#x5371;&#x96aa;&#x7684;&#x964d;&#x4e3b;&#x52d5;&#x8c93;&#x7624;&#x75c5;&#x4eba;&#x7528;&#x652f;&#x67b6;&#x6cbb;&#x7642;&#x6709;&#x597d;&#x8655;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2007-05-19T00:59:56+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/040ab362ce600dafeec4d17edd13c71f-20.html#unique-entry-id-20</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/040ab362ce600dafeec4d17edd13c71f-20.html#unique-entry-id-20</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">也就是說用支架TEVAR來對無症狀且高手術危險的降主動貓瘤病人治療，是合理的哦！</span></p>]]></content:encoded></item><item><title>&#x4e3b;&#x52d5;&#x8108;&#x75be;&#x75c5;&#x6cbb;&#x7642;&#x7684;&#x65b0;&#x5229;&#x5668;&#xfe63;&#x4e3b;&#x52d5;&#x8108;&#x8840;&#x7ba1;&#x5167;&#x652f;&#x67b6;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2007-07-17T10:15:28+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/af7a401a5ce2fda45865f627cbb8f5a6-19.html#unique-entry-id-19</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/af7a401a5ce2fda45865f627cbb8f5a6-19.html#unique-entry-id-19</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">新的治療方式，對於患者的心肺功能的考驗較低，傷口小，恢復快，併發症自然也降到最低。</span></p>]]></content:encoded></item><item><title>&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;TEVAR: &#x5275;&#x50b7;&#x6027;&#x4e3b;&#x52d5;&#x8108;&#x5916;&#x50b7;&#x7684;&#x8840;&#x7ba1;&#x8154;&#x5167;&#x6cbb;&#x7642;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2007-04-13T22:44:29+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/329d12d17b109061665ac6728edeefac-18.html#unique-entry-id-18</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/329d12d17b109061665ac6728edeefac-18.html#unique-entry-id-18</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">這是從University of Maryland出來的報告。在這篇文章中描述了二十個病人的治療，全部用Endovascular treatment. 三十天的死亡率是20%，都是因為合併的身體其它傷害,相當的不錯。<br /></span>]]></content:encoded></item><item><title>&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;TEVAR: &#x9069;&#x7528;&#x65bc;ruptured AAA&#xff08;&#x7834;&#x88c2;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#xff09;? </title><dc:creator>purplemind@mac.com</dc:creator><category>&#x5c08;&#x696d;&#x77e5;&#x8b58;</category><dc:date>2007-04-11T20:53:58+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/0fb111155d5637a7dad2d9737573b492-17.html#unique-entry-id-17</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/0fb111155d5637a7dad2d9737573b492-17.html#unique-entry-id-17</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; "><a href="血循不穩的破裂主動脈瘤病人作支架治療會有最有的益處（相對於緊急開腹術而言），所以不要輕言放棄而只治對穩定的病人施以支架治療！" rel="external">血循不穩的破裂主動脈瘤病人作支架治療會有最有的益處</a></span><span style="font:12px LiHeiPro; ">（相對於緊急開腹術而言），所以不要輕言放棄而只治對穩定的病人施以支架治療！</span>]]></content:encoded></item><item><title>&#x8179;&#x8154;&#x93e1;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x5207;&#x9664;&#xff0c;&#x53f0;&#x7063;&#x7b2c;&#x4e00;&#x4f8b;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-04-08T15:06:59+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/f8d3be4f7d3e47f47fd26d23ff75b458-16.html#unique-entry-id-16</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/f8d3be4f7d3e47f47fd26d23ff75b458-16.html#unique-entry-id-16</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">日前，亞東醫院完成亞洲第一例的腹腔鏡主動脈瘤切除手術</span>]]></content:encoded></item><item><title>&#x9152;&#x7cbe;&#x6703;&#x589e;&#x52a0;&#x767c;&#x751f;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x5371;&#x96aa;&#xff01;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-04-05T17:34:25+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/a562efabb4adaaf774c3f97ae6aa9108-15.html#unique-entry-id-15</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/a562efabb4adaaf774c3f97ae6aa9108-15.html#unique-entry-id-15</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">也就是說，每天的酒精消耗不要超過兩杯喔。</span>]]></content:encoded></item><item><title>&#x9577;&#x5e9a;&#x7b2c;&#x4e00;&#x4f8b;&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x624b;&#x8853;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-03-23T00:17:38+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/4952147aacf90d85a583688a516c9d08-14.html#unique-entry-id-14</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/4952147aacf90d85a583688a516c9d08-14.html#unique-entry-id-14</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">林口長庚醫院在今天執行了本院的第一例胸主動脈瘤的放置手術</span>]]></content:encoded></item><item><title>&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x652f;&#x67b6;&#x6cbb;&#x7642;: &#x5c0d;&#x9ad8;&#x5371;&#x96aa;&#x7fa4;&#x75c5;&#x60a3;&#x7684;&#x6548;&#x679c;&#x6bd4;&#x8f03;&#x5b89;&#x5168;&#xff01;EVAR vs Open on High risk patients</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-02-23T21:18:32+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/78b00ff6b024f4c2b8533c6701f89d5b-13.html#unique-entry-id-13</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/78b00ff6b024f4c2b8533c6701f89d5b-13.html#unique-entry-id-13</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">這一篇在Journal of Vascular Surgery上</span><span style="font:12px Verdana, serif; "><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17263992&query_hl=2&itool=pubmed_docsum" rel="external">2007 Feb;45(2):227-233</a></span><span style="font:12px LiHeiPro; ">的報告，敍述了腹主動脈瘤的支架治療在高危險群病人身上的療效。報告中，這是一個大規模的統計，統計在高手術危險群患者的腹主動脈瘤治療，統計看看用支架和用傳統的差別。</span>]]></content:encoded></item><item><title>&#x6025;&#x6027;B&#x578b;&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x525d;&#x96e2;Type B dissection&#xff0c;&#x7528;&#x652f;&#x67b6;&#x7684;&#x6cbb;&#x7642;&#x6548;&#x679c;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-02-22T23:06:02+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/1bbb7689413bc5f0f873d44b5c9ce370-12.html#unique-entry-id-12</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/1bbb7689413bc5f0f873d44b5c9ce370-12.html#unique-entry-id-12</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">專業期刊ATS上的一篇</span><span style="font:12px LiHeiPro; "><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17307460&query_hl=5&itool=pubmed_docsum" rel="external">文章</a></span><span style="font:12px LiHeiPro; ">,是奧地利醫生作的研究。他們研究的對象是有症狀的，急性B型胸主動脈剝離Type B dissection，用支架的治療效果。結果，只有百分之十的死亡率。結論是百分之九十的假腔，在有放支架的部分，都被栓塞了！但支架血管的遠端，則栓塞率只有六十！（這部份是長期比較令人擔心的）至於在腹主動脈部分，則只有百分之二十的假腔栓塞了。</span>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x5728;&#x53f0;&#x7063;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-02-17T16:55:44+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/b6cb4fe247d9e286839abb8185207610-11.html#unique-entry-id-11</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/b6cb4fe247d9e286839abb8185207610-11.html#unique-entry-id-11</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">胸主動脈的常見疾病包括有</span><span style="font:12px LiHeiPro; "><a href="http://www.tzuchi.com.tw/tzuchi/News_HotNews/Default.aspx?Action=ViewDetail&NewsType=0&NewsCategory=0&AppSiteID=&IdentityID=285" rel="external">主動脈剝離</a></span><span style="font:12px LiHeiPro; ">（A型和B型）以及主動脈瘤。以目前最新的科技而言，B型的主動脈剝離以及主動脈弓或是降主動脈的主動脈瘤都有機會以低侵襲性的微創手術來治療。用支架來治療，不僅較安全，也可以免去開胸的大手術和可能的併發症。<br />台灣在2006年底正式核准了胸主動脈支架上巿之後，</span><span style="font:12px LiHeiPro; "><a href="http://www.kuolin.org/82_20061120.htm" rel="external">台大</a></span><span style="font:12px LiHeiPro; ">和</span><span style="font:12px LiHeiPro; "><a href="http://www.rti.org.tw/News/NewsContentHome.aspx?t=1&NewsID=61741" rel="external">榮總</a></span><span style="font:12px LiHeiPro; ">都已開始進行這項微創手術的治療，成效不錯，可以說是患者在傳統手術之外的另一個選擇。<br /></span>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#xff1a;&#x652f;&#x67b6;&#x548c;&#x50b3;&#x7d71;&#x624b;&#x8853;&#x6bd4;&#x8f03;&#x7684;&#x7814;&#x7a76;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-02-02T00:29:45+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/9278d75a50b44831a2e5ab67bf09d92c-9.html#unique-entry-id-9</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/9278d75a50b44831a2e5ab67bf09d92c-9.html#unique-entry-id-9</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">第一個多中心，大規模，比較胸主動脈瘤的治療方式</span>]]></content:encoded></item><item><title>&#x7f8e;&#x570b;Medicare&#x4fdd;&#x96aa;&#x958b;&#x59cb;&#x63d0;&#x4f9b;&#x514d;&#x8cbb;&#x7684;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x8d85;&#x97f3;&#x6ce2;&#x7be9;&#x6aa2;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2007-01-06T23:24:30+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/d94f9083625c597969aff1b13a4d4c7c-8.html#unique-entry-id-8</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/d94f9083625c597969aff1b13a4d4c7c-8.html#unique-entry-id-8</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">2007美國Medicare保險(對象為65歲以上及糖尿病，洗腎者）開始提供免費的腹主動脈瘤超音波篩檢</span>]]></content:encoded></item><item><title>&#x80f8;&#x4e3b;&#x52d5;&#x8108;&#x652f;&#x67b6;&#x8840;&#x7ba1;&#x9032;&#x5165;&#x53f0;&#x7063;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x6d88;&#x606f;&#xff0c;&#x77ed;&#x8a0a;&#xff0c;&#x89e3;&#x91cb;</category><dc:date>2006-10-30T01:24:00+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/c3baa3446909900fa26ca42720365965-7.html#unique-entry-id-7</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/c3baa3446909900fa26ca42720365965-7.html#unique-entry-id-7</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">國內終於許可了第一個</span><span style="font:12px LiHeiPro; "><a href="../(null)/(null)" rel="external">胸主動脈支架</a></span><span style="font:12px LiHeiPro; ">的許可(Cook; TX2 stentgraft)。相信不久之後，有一部...</span>]]></content:encoded></item><item><title>&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x65b0;&#x7642;&#x6cd5;-&#x4f4e;&#x4fb5;&#x8972;&#x6027;&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x8840;&#x7ba1;&#x5167;&#x652f;&#x67b6;&#x624b;&#x8853;&#xd;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2006-10-13T12:34:51+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/8b1d78d3d2b34db14bace95ba09ef120-6.html#unique-entry-id-6</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/8b1d78d3d2b34db14bace95ba09ef120-6.html#unique-entry-id-6</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">李先生，八十三歲，身體還算硬朗。但是自從一年前在一次身體檢查中發現了腹部的主動脈瘤之後，心中著實忐忑不安。</span></p>]]></content:encoded></item><item><title>&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x7684;&#x767c;&#x73fe;&#x53ca;&#x6cbb;&#x7642;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2006-10-13T12:31:48+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/cf1ae05aa957f1ee0b7fed24ba4bda6b-5.html#unique-entry-id-5</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/cf1ae05aa957f1ee0b7fed24ba4bda6b-5.html#unique-entry-id-5</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">在血管外科的領域中，</span><span style="font:12px LiHeiPro; "><a href="web.mac.com/purplemind/iWeb/EVAR" rel="external">腹主動脈瘤</a></span><span style="font:12px LiHeiPro; ">是一個無明顯症狀且容易忽略，但是具生命威脅的主要疾病。</span></p>]]></content:encoded></item><item><title>&#x8179;&#x90e8;&#x4e3b;&#x52d5;&#x8108;&#x8840;&#x7ba1;&#x7624;&#x4ecb;&#x7d39;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2006-10-13T12:13:22+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/7032d82ffb10e81d2344c815b8840252-4.html#unique-entry-id-4</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/7032d82ffb10e81d2344c815b8840252-4.html#unique-entry-id-4</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">王先生，七十五歲，平日有高血壓病史。因為持續性的腹部腫脹，食慾不振而且不斷嘔吐而至地區醫院就醫。理學檢查發現腹部一搏動性腫塊，懷疑是主動脈瘤而轉送至本院。</span></p>]]></content:encoded></item><item><title>&#x5f9e;&#x611b;&#x56e0;&#x65af;&#x5766;&#x8ac7;&#x8d77;-&#x8179;&#x4e3b;&#x52d5;&#x8108;&#x7624;&#x6cbb;&#x7642;&#x7684;&#x6f14;&#x9032;&#xd;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2006-10-13T11:25:09+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/57b45d3c95ce35ebb469b8170fa86c99-3.html#unique-entry-id-3</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/57b45d3c95ce35ebb469b8170fa86c99-3.html#unique-entry-id-3</guid><content:encoded><![CDATA[<p style="text-align:justify;"><span style="font:12px LiHeiPro; ">二十世紀最頂尖也最具影響力的科學家，亞伯特．愛因斯坦，生於一八七九年的德國，一九五五年因為腹主動脈瘤破裂過逝於美國普林斯頓，享年七十六歲。</span></p>]]></content:encoded></item><item><title>&#x65e9;&#x671f;&#x767c;&#x73fe;&#x65e9;&#x671f;&#x6cbb;&#x7642;&#xff0c;&#x5371;&#x96aa;&#x7684;&#x4e3b;&#x52d5;&#x8108;&#x7624;</title><dc:creator>purplemind@mac.com</dc:creator><category>&#x885b;&#x6559;&#x5e38;&#x8b58;</category><dc:date>2006-10-13T11:24:02+08:00</dc:date><link>http://www.vascular.idv.tw/page1/files/fdeebe394f47e0830323f4451051b0e4-2.html#unique-entry-id-2</link><guid isPermaLink="true">http://www.vascular.idv.tw/page1/files/fdeebe394f47e0830323f4451051b0e4-2.html#unique-entry-id-2</guid><content:encoded><![CDATA[<span style="font:12px LiHeiPro; ">知名的百老匯音樂劇&ldquo;吉屋出租&ldquo;前些時候在台北由演出，引起不小的迴響。在觀眾讚嘆並欣賞這齣充滿原創力及生命力的戲劇的同時，可能並不知道，它的作者，</span>]]></content:encoded></item></channel>
</rss>
